Capillary rarefaction and renal interstitial fibrosis: a cellular perspective

doi:10.3877/cma.j.issn.2095-3216.2020.03.007

Abstract

Abstract:

Capillary rarefaction of the kidney is not only a result of CKD, but also a crucial link to promote the progression of CKD to renal interstitial fibrosis (RIF). Learning about the mechanism that may cause the renal capillary rarefaction is of great significance for improving vascular rarefaction and angiogenesis, as well as reducing the development of RIF. This review started with the renal cells around capillaries, such as endothelial cells, pericytes, and endothelial progenitor cells, then summarized their pathophysiological processes that may affect the normal vascular network structure of the kidney and their possible involvement in the repair mechanism of angiogenesis, so as to provide new treatment ideas for improving RIF and slowing down the CKD progression.

Key words: Capillary rarefaction, Renal interstitial fibrosis, Endothelial cells, Pericytes, Endothelial progenitor cells

Xuejiao Wei, Yangyang Zhang, Xiaoyu Zhu, Xiu Huang, Lili Jiang, Dan Zhao, Mengtuan Long, Yujun Du. Capillary rarefaction and renal interstitial fibrosis: a cellular perspective[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2020, 09(03): 124-126.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2020.03.007

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2020/V09/I03/124

References 28

[1]	Herzlinger D, Hurtado R. Patterning the renal vascular bed [J]. Semin Cell Dev Biol, 2014, 36: 50-56.
[2]	Afsar B, Afsar RE, Dagel T, et al. Capillary rarefaction from the kidney point of view [J]. Clin Kidney J, 2018, 11(3): 295-301.
[3]	Kida Y, Tchao BN, Yamaguchi I. Peritubular capillary rarefaction: a new therapeutic target in chronic kidney disease [J]. Pediatr Nephrol, 2014, 29(3): 333-342.
[4]	Mayer G. Capillary rarefaction, hypoxia, VEGF and angiogenesis in chronic renal disease [J]. Nephrol Dial Transplant, 2011, 26(4): 1132-1137.
[5]	Ballermann BJ, Obeidat M. Tipping the balance from angiogenesis to fibrosis in CKD [J]. Kidney Int Suppl (2011), 2014, 4(1): 45-52.
[6]	Gewin L, Zent R, Pozzi A. Progression of chronic kidney disease: too much cellular talk causes damage [J]. Kidney Int, 2017, 91(3): 552-560.
[7]	Tanaka T, Nangaku M. Angiogenesis and hypoxia in the kidney [J]. Nat Rev Nephrol, 2013, 9(4): 211-222.
[8]	Liu S, Soong Y, Seshan SV, et al. Novel cardiolipin therapeutic protects endothelial mitochondria during renal ischemia and mitigates microvascular rarefaction, inflammation, and fibrosis [J]. Am J Physiol Renal Physiol, 2014, 306(9): F970-F980.
[9]	Mendes KL, Lelis DF, Santos SHS. Nuclear sirtuins and inflammatory signaling pathways [J]. Cytokine Growth Factor Rev, 2017, 38: 98-105.
[10]	Kida Y, Zullo JA, Goligorsky MS. Endothelial sirtuin 1 inactivation enhances capillary rarefaction and fibrosis following kidney injury through Notch activation [J]. Biochem Biophys Res Commun, 2016, 478(3): 1074-1079.
[11]	He X, Zeng H, Chen ST, et al. Endothelial specific SIRT3 deletion impairs glycolysis and angiogenesis and causes diastolic dysfunction [J]. J Mol Cell Cardiol, 2017, 112: 104-113.
[12]	Wu J, Zeng Z, Zhang W, et al. Emerging role of SIRT3 in mitochondrial dysfunction and cardiovascular diseases [J]. Free Radic Res, 2019, 53(2): 139-149.
[13]	He X, Zeng H, Chen JX. Emerging role of SIRT3 in endothelial metabolism, angiogenesis, and cardiovascular disease [J]. J Cell Physiol, 2019, 234(3): 2252-2265.
[14]	Fligny C, Duffield JS. Activation of pericytes: recent insights into kidney fibrosis and microvascular rarefaction [J]. Curr Opin Rheumatol, 2013, 25(1): 78-86.
[15]	Pan S－Y, Chang Y－T, Lin S－L. Microvascular pericytes in healthy and diseased kidneys [J]. Int J Nephrol Renovasc Dis, 2014, 7: 39-48.
[16]	Schrimpf C, Teebken OE, Wilhelmi M, et al. The role of pericyte detachment in vascular rarefaction [J]. J Vasc Res, 2014, 51(4): 247-258.
[17]	Eklund L, Saharinen P. Angiopoietin signaling in the vasculature [J]. Exp Cell Res, 2013, 319(9): 1271-1280.
[18]	Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin－2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis [J]. Science, 1997, 277(5322): 55-60.
[19]	Chiang WC, Huang YC, Fu TI, et al. Angiopoietin 1 influences ischemic reperfusion renal injury via modulating endothelium survival and regeneration [J]. Mol Med, 2019, 25(1): 5.
[20]	Loganathan K, Salem Said E, Winterrowd E, et al. Angiopoietin－1 deficiency increases renal capillary rarefaction and tubulointerstitial fibrosis in mice [J]. PLoS One, 2018, 13(1): e0189433.
[21]	Lin SL, Chang FC, Schrimpf C, et al. Targeting endothelium－pericyte cross talk by inhibiting VEGF receptor signaling attenuates kidney microvascular rarefaction and fibrosis [J]. Am J Pathol, 2011, 178(2): 911-923.
[22]	Wong S－P, Rowley JE, Redpath AN, et al. Pericytes, mesenchymal stem cells and their contributions to tissue repair [J]. Pharmacol Ther, 2015, 151: 107-120.
[23]	Chade AR, Zhu X－Y, Krier JD, et al. Endothelial progenitor cells homing and renal repair in experimental renovascular disease [J]. Stem Cells, 2010, 28(6): 1039-1047.
[24]	Fernandes T, Nakamuta JS, Magalhaes FC, et al. Exercise training restores the endothelial progenitor cells number and function in hypertension: implications for angiogenesis [J]. J Hypertens, 2012, 30(11): 2133-2143.
[25]	Cantaluppi V, Gatti S, Medica D, et al. Microvesicles derived from endothelial progenitor cells protect the kidney from ischemia－reperfusion injury by microRNA－dependent reprogramming of resident renal cells [J]. Kidney Int, 2012, 82(4): 412-427.
[26]	Yang J, Wang M, Zhu F, et al. Putative endothelial progenitor cells do not promote vascular repair but attenuate pericyte－myofibroblast transition in UUO－induced renal fibrosis [J]. Stem Cell Res Ther, 2019, 10(1): 104.
[27]	He J, Liu X, Su C, et al. Inhibition of mitochondrial oxidative damage improves reendothelialization capacity of endothelial progenitor cells via SIRT3 (Sirtuin 3)－enhanced SOD2 (superoxide dismutase 2) deacetylation in hypertension [J]. Arterioscler Thromb Vasc Biol, 2019, 39(8): 1682-1698.
[28]	Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross－sectional survey [J]. Lancet, 2012, 379(9818): 815-822.

Please choose a citation manager

Content to export